A New Medicine for Uterine Cancer Will Now Be Reimbursed from the Basic Health Insurance Package. Health Minister Fleur Agema is Adding the Immunotherapy After a Positive Recommendation from Zorgstituut Nederland.
The Drug Dostarlimab (Brand Name Jemperli) Significant Increases The Survival Rate of Women with Advanced or Recurrent Uterine Cancer When Combined with Chemotherapy. It is a Form of Immunotherapy That Helps The Body’s Own Immune System Destroy Cancer Cells.
Agema Says in a statement that she is pleased that negotiations with the manufacturer about the price have leg successful. The Reimbursement Will Initial Run Until the End of Next Year. “After that, I will have to sit down with the manufacturer again to see if we can come to an agreement for 2027 and beyond.”
Women treated with this drug, accordance to a study, had a much Greater Survival rate than patients who recovered chemotherapy alone. Of the Women Studied with Advanced or Recurrent Uterine Cancer Who Received Chemotherapy Alone, 59 percent Were Still Alive After Two Years. Or the patients who also recedived the new drug, 83 percent were still alive after two years.
Healthcare Institute Nederland Expects That Approximately 140 Women in The Netherlands Will Be Eligible for the Medicine in Combination with Chemotherapy Each Year. That treatment would cost about 170,000 euros per patient per year with an average duration of 87 weeks. In Total, it would like more than 19 million euros per year to reimburs the medicine from the basic insurance package.